Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Long-Term Investments: 2021-2024

Historic Long-Term Investments for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Dec 2024 value amounting to $80.6 million.

  • 4D Molecular Therapeutics' Long-Term Investments rose 37.69% to $67.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.2 million, marking a year-over-year increase of 37.69%. This contributed to the annual value of $80.6 million for FY2024, which is 635.65% up from last year.
  • 4D Molecular Therapeutics' Long-Term Investments amounted to $80.6 million in FY2024, which was up 635.65% from $11.0 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Long-Term Investments peaked at $80.6 million during FY2024, and registered a low of $4.9 million during FY2022.
  • In the last 3 years, 4D Molecular Therapeutics' Long-Term Investments had a median value of $11.0 million in 2023 and averaged $32.1 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Long-Term Investments plummeted by 92.75% in 2022 and then soared by 635.65% in 2024.
  • Over the past 4 years, 4D Molecular Therapeutics' Long-Term Investments (Yearly) stood at $67.7 million in 2021, then slumped by 92.75% to $4.9 million in 2022, then spiked by 123.19% to $11.0 million in 2023, then spiked by 635.65% to $80.6 million in 2024.